Corvus Pharmaceuticals, Inc. reported financial results for the three and six months ended June 30, 2026. The company held $215.2 million in cash, cash equivalents, and marketable securities as of June 30, 2026, providing a runway into the second quarter of 2028. Research and development expenses for the three months ended June 30, 2026 totaled $16.0 million, resulting in a net loss of $18.0 million compared to an $8.0 million loss in the same period last year. The company provided a business update on its lead candidate soquelitinib, noting that enrollment is ongoing for the registrational Phase 3 trial in relapsed/refractory peripheral T-cell lymphoma and the Phase 2 atopic dermatitis trial. Corvus also invested $5.0 million in partner Angel Pharmaceuticals to support their clinical trials.

Ian T. Clark resigned from the board of directors of Corvus Pharmaceuticals, Inc. on July 21, 2026, effective July 22, 2026, ending over nine years of service. The company operates in the biotechnology industry and develops therapeutics for immunology and oncology.